Tom 13, Nr 1 (2018)
GŁOS EKSPERTA
Opublikowany online: 2018-04-10
Wyświetlenia strony
810
Wyświetlenia/pobrania artykułu
4712
Leczenie przeciwzakrzepowe u pacjentów z migotaniem przedsionków i implantowanym stentem w świetle nowych badań. Zmiana paradygmatu
Kardiol Inwazyjna 2018;13(1):3-9.
Streszczenie
Częstość występowania migotania przedsionków (AF) w populacji osób powyżej 20 roku życia wynosi około 3%, ale odsetki te w procesie starzenia, u chorych w nadciśnieniem tętniczym, chorobą niedokrwienną serca, niewydolnością krążenia , cukrzycą, wadami zastawkowymi, otyłością i przewlekłą niewydolnością nerek – znacznie wzrastają
Słowa kluczowe: migotanie przedsionkówimplantacja stentupotrójna terapia antykrzepliwapodwójna terapia antykrzepliwa
Referencje
- Kirchhof P, Benussi S, Kotecha D, et al. Wytyczne ESC dotyczące leczenia migotania przedsionków w 2016 roku, opracowane we współpracy z EACTS. Kardiologia Polska. 2016; 74(12): 1359–1469.
- Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017; 39(3): 213–260.
- Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17(10): 1467–1507.
- Palmerini T, Sangiorgi D, Valgimigli M, et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol. 2015; 65(11): 1092–1102.
- Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012; 379(9824): 1393–1402.
- Sen H, Lam M, Löwik M, et al. Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents. JACC: Cardiovascular Interventions. 2015; 8(7): 889–899.
- Giustino G, Baber U, Sartori S, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015; 65(13): 1298–1310.
- Dewilde WJM, Oirbans T, Verheugt FWA, et al. WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381(9872): 1107–1115.
- Fiedler KA, Maeng M, Mehilli J, et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015; 65(16): 1619–1629.
- Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016; 375(25): 2423–2434.
- Cannon CP, Bhatt DL, Oldgren J, et al. RE-DUAL PCI Steering Committee and Investigators. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017; 377(16): 1513–1524.
- Lamberts M, Gislason G, Olesen J, et al. Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention. Journal of the American College of Cardiology. 2013; 62(11): 981–989.
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 16(348): 1329–1339.
- Gibson CM, Pinto DS, Chi G, et al. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. 2017; 135(4): 323–333.
- Bhatt DL. O PIONEERs! The Beginning of the End of Full-Dose Triple Therapy with Warfarin? Circulation. 2017; 135(4): 334–337.
- Jolly SS, Natarajan MK. Atrial Fibrillation and PCI - Do We Still Need Aspirin? N Engl J Med. 2016; 375(25): 2490–2492.
- Cannon CP, Bhatt DL, Oldgren J, et al. RE-DUAL PCI Steering Committee and Investigators. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017; 377(16): 1513–1524.
- Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012; 172(5): 397–402.
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010; 363(19): 1875–1876.
- Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012; 125(5): 669–676.
- Artang R, Rome E, Nielsen JD, et al. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol. 2013; 112(12): 1973–1979.
- Loke YK, Pradhan S, Yeong JKY, et al. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. 2014; 78(4): 707–717.
- Verheugt FWA. Combined antiplatelet and novel oral anticoagulant therapy after acute coronary syndrome: is three a crowd? Eur Heart J. 2013; 34(22): 1618–1620.
- Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014; 384(9943): 599–606.
- Grajek S, Michlak M, Gwizdała A, et al. Patients treated with bivalirudin still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomized clinical trials of bivalirudin and heparin for percutaneous coronary interventions. Kardiol Pol. 2018 [Epub ahead of print].
